Effect of Renal Function on the Pharmacodynamics of Argatroban
- 1 January 2004
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 38 (1), 25-29
- https://doi.org/10.1345/aph.1d163
Abstract
BACKGROUND: Argatroban is a direct thrombin inhibitor used to treat heparin-induced thrombocytopenia (HIT). Argatroban is primarily cleared by hepatic mechanisms, with only small amounts of unchanged drug cleared by the kidneys.OBJECTIVE: To assess the effects of renal function on argatroban dose and activated partial thromboplastin time (aPTT).METHODS: Patients treated with argatroban were identified and prospectively screened. Patients with liver dysfunction were excluded from the analysis. Charts and laboratory data were reviewed daily until a therapeutic aPTT was reached or argatroban was discontinued. Data points collected included age, weight, gender, admitting diagnosis, past medical history, indication for anticoagulation, indication for argatroban, initial dose, goal aPTT, titration instructions, liver function tests, serum creatinine (Scr), blood urea nitrogen, and estimated creatinine clearance (Clcr).RESULTS: A total of 66 patients were evaluated and 44 met criteria for inclusion. Baseline Scrwas elevated at 1.5 mg/dL (0.9, 2.3; median 25th, 75th percentile), with an estimated Clcr40 mL/min/1.73 m2(26, 74). The median dose of argatroban to reach the predefined therapeutic range was 1 μg/kg/min (0.68, 2), with a corresponding aPTT of 60 seconds (54, 66). After univariate analysis, Clcrsignificantly predicted the therapeutic dose (coefficient b ± SE 0.019 ± 0.004; r20.35; p < 0.001). Covariates that predicted dose were the presence of HIT (coefficient b ± SE −0.61 ± 0.3; p = 0.045), history of myocardial infarction (coefficient b ± SE −0.74 ± 0.3; p = 0.02), and an indication for anticoagulation of deep-vein thrombosis/pulmonary embolism (coefficient b ± SE 0.69 ± 0.3; p = 0.03).CONCLUSIONS: Estimated Clcrsignificantly predicted the dose of argatroban needed to reach a therapeutic aPTT.Keywords
This publication has 8 references indexed in Scilit:
- Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolismBritish Journal of Haematology, 2001
- Recombinant Hirudin in Clinical PracticeCirculation, 2001
- High Plasma Levels of Factor VIII and the Risk of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2000
- The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal DysfunctionPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999
- Heparin-Induced ThrombocytopeniaDrug Safety, 1997
- A 14-year study of heparin-induced thrombocytopeniaAmerican Journal Of Medicine, 1996
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976